CXCR4 and neoplasm: Consistent with outcome of the survival analysis, CXCR4 was significantly upregulated in GC patients with younger ages and worse tumor status, including the grade 3 (p = 0.0062) and M1 stage, than in patients with other tumor statuses (p = 0.0194; Figure 3A).